Arthneeti

Krebs Biochemicals & Industries Q2 FY27 Share Price & Earnings Call Analysis

₹55.92+2.57% today
Market cap
₹121 Cr
Price to sales
4.48
Debt to equity
0.00
52W high / low
₹71.3 / ₹39.8
Sales growth (5Y)
-15.07%
EBITDA margin
-6.22%
Net profit margin
-71.34%
Promoter holding
72.74%
Sales (last year)
₹27 Cr

Potential multibaggers · Q2 FY27

This quarter's potential multibaggers
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Krebs Biochem rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Financials of Krebs Biochem

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Krebs Biochem

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%72.74%
FIIs +0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%0.50%
Public +26.77%26.75%26.75%26.76%26.76%26.75%26.76%26.76%26.76%26.77%26.76%26.75%
No. of Shareholders8,9908,9098,8489,4259,0918,7989,1188,9128,7108,5538,5218,533

Pros & Cons

Krebs Biochem

Key positives and risks surfaced from the company insights section.

Pros
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -15.1% over past five years.
Raw Insights
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -15.1% over past five years.

Financials of Krebs Biochem

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +14.8912.9811.9712.8912.8611.476.105.484.177.276.816.985.79
Expenses +15.7915.0715.0915.0815.5816.1811.517.576.976.977.676.167.72
Operating Profit-0.90-2.09-3.12-2.19-2.72-4.71-5.41-2.09-2.800.30-0.860.82-1.93
OPM %-6.04%-16.10%-26.07%-16.99%-21.15%-41.06%-88.69%-38.14%-67.15%4.13%-12.63%11.75%-33.33%
Other Income +0.170.030.210.030.090.250.340.010.010.002.000.160.04
Interest1.131.191.271.321.421.561.611.651.731.791.911.881.90
Depreciation1.711.731.671.691.711.721.571.601.621.631.571.591.61
Profit before tax-3.57-4.98-5.85-5.17-5.76-7.74-8.25-5.33-6.14-3.12-2.34-2.49-5.40
Tax %0.00%0.00%0.00%0.00%0.00%0.00%0.24%0.00%0.00%0.00%0.00%0.00%0.00%
Net Profit +-3.57-4.98-5.85-5.17-5.76-7.74-8.27-5.32-6.14-3.13-2.34-2.48-5.40
EPS in Rs-1.66-2.31-2.71-2.40-2.67-3.59-3.84-2.47-2.85-1.45-1.09-1.15-2.50

Financials of Krebs Biochem

Profit & Loss

Annual income statement trend

Mar 2015 6mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +01334483354605250432427
Expenses +5141141585271946859582929
Operating Profit-5-12-8-8-10-19-18-34-16-9-15-5-2
OPM %-1,088%-248%-22%-20%-56%-33%-57%-30%-17%-35%-23%-6%
Other Income +31-0-1001110122
Interest4135666535677
Depreciation2444455677766
Profit before tax-8-16-16-18-20-29-28-45-25-20-27-17-13
Tax %0%0%0%0%0%0%0%0%0%0%0%0%
Net Profit +-8-16-16-18-20-29-28-45-25-20-27-17-13
EPS in Rs-6.82-10.33-9.67-10.73-12.03-16.04-14.45-20.65-11.45-9.15-12.50-7.85-6.19
Dividend Payout %0%0%0%0%0%0%0%0%0%0%0%0%

Financials of Krebs Biochem

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital10131414171820222222222222
Reserves9-0-12-32-31-43-62-97-121-141-168-184-192
Borrowings +613148565366111143183194212225227
Other Liabilities +29737387103939112291104103101102
Total Liabilities108116122126142134159190175178169163159
Fixed Assets +5893102101101105118139147150146142139
CWIP011443412842322
Investments0000000000000
Other Assets +50131621382429432426202018
Total Assets108116122126142134159190175178169163159

Financials of Krebs Biochem

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +-45-15-11-64-36-15-17-252-8-2
Cash from Investing Activity +-3-4-5-3-4-10-23-23-13-8-5-4
Cash from Financing Activity +541316917293840376136
Net Cash Flow6-6-0017-171-1-000-0
Free Cash Flow-48-23-17-9-1-45-40-41-36-5-11-5
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit924%123%140%83%-40%191%83%51%157%-27%52%35%

Financials of Krebs Biochem

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1018032222541400
Inventory Days14,7042,162337142345234230170543396
Days Payable32,2504,3605103395212923402171,0511,192
Cash Conversion Cycle-17,536-2,018-170-175-174-57-106-44-494-7950
Working Capital Days-6,532-2,132-275-315-267-187-261-232-322-787-1,593
ROCE %-26%-26%-26%-36%-57%-40%-57%-29%-19%-30%-15%

Continue your research

What Krebs Biochem's management said in earlier quarters